ArticleInternational journal of nanomedicine2012
Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 48 citations in OpenAlex.
- Optimization of a Modular Nanotransporter Design for Targeted Intracellular Delivery of Photosensitizer.Pharmaceutics · 2024Article
- Prospects of Using Protein Engineering for Selective Drug Delivery into a Specific Compartment of Target Cells.Pharmaceutics · 2023Review
- Mouse Syngeneic Melanoma Model with Human Epidermal Growth Factor Receptor Expression.Pharmaceutics · 2022Article
- Nrf2/Keap1/ARE signaling: Towards specific regulation.Life sciences · 2022Review
- Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape.Pharmaceutics · 2021Review
- Soluble Cyanobacterial Carotenoprotein as a Robust Antioxidant Nanocarrier and Delivery Module.Antioxidants (Basel, Switzerland) · 2020Article
- Targeted Delivery ofFrontiers in pharmacology · 2020Article
- New Recombinant Carriers Binding Specifically to the Epidermal Growth Factor Receptor.Doklady. Biochemistry and biophysics · 2020Article
- MNT Optimization for Intracellular Delivery of Antibody Fragments.Doklady. Biochemistry and biophysics · 2018Article
- Study of Biodistribution of the Modular Nanotransporters after Systemic Administration in Murine Cloudman S91 Melanoma Model.Doklady. Biochemistry and biophysics · 2018Article
- Modular Nanotransporters for Nuclear-Targeted Delivery of Auger Electron Emitters.Frontiers in pharmacology · 2018Review
- Editorial: Targeted Subcellular Delivery of Anti-cancer Agents.Frontiers in pharmacology · 2018Article
- Targeted Intracellular Delivery of Antibodies: The State of the Art.Frontiers in pharmacology · 2018Review
- Antitumor Activity of Auger Electron EmitterFrontiers in pharmacology · 2018Article
- Specific Targeting of Melanotic Cells with Peptide Ligated Photosensitizers for Photodynamic Therapy.Scientific reports · 2017Article
- A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.Biomedical physics & engineering express · 2017Article
- Development and evaluation of a new modular nanotransporter for drug delivery into nuclei of pathological cells expressing folate receptors.Drug design, development and therapy · 2017Article
- Preparation, cytotoxicity, and in vivo antitumor efficacy ofInternational journal of nanomedicine · 2017Article
- Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.Current pharmaceutical design · 2015Review
- Current State of Animal (Mouse) Modeling in Melanoma Research.Cancer growth and metastasis · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundModular nanotransporters (MNT) are recombinant multifunctional polypeptides created to exploit a cascade of cellular processes, initiated with membrane receptor recognition to deliver selective short-range and highly cytotoxic therapeutics to the cell nucleus. This research was designed for in vivo concept testing for this drug delivery platform using two modular nanotransporters, one targeted to the α-melanocyte-stimulating hormone (αMSH) receptor overexpressed on melanoma cells and the other to the epidermal growth factor (EGF) receptor overexpressed on several cancers, including glioblastoma, and head-and-neck and breast carcinoma cells.
methodsIn vivo targeting of the modular nanotransporter was determined by immuno-fluorescence confocal laser scanning microscopy and by accumulation of (125)I-labeled modular nanotransporters. The in vivo therapeutic effects of the modular nanotransporters were assessed by photodynamic therapy studies, given that the cytotoxicity of photosensitizers is critically dependent on their delivery to the cell nucleus.
resultsImmunohistochemical analyses of tumor and neighboring normal tissues of mice injected with multifunctional nanotransporters demonstrated preferential uptake in tumor tissue, particularly in cell nuclei. With (125)I-labeled MNT{αMSH}, optimal tumor:muscle and tumor:skin ratios of 8:1 and 9.8:1, respectively, were observed 3 hours after injection in B16-F1 melanoma-bearing mice. Treatment with bacteriochlorin p-MNT{αMSH} yielded 89%-98% tumor growth inhibition and a two-fold increase in survival for mice with B16-F1 and Cloudman S91 melanomas. Likewise, treatment of A431 human epidermoid carcinoma-bearing mice with chlorin e(6)- MNT{EGF} resulted in 94% tumor growth inhibition compared with free chlorin e(6), with 75% of animals surviving at 3 months compared with 0% and 20% for untreated and free chlorin e(6)-treated groups, respectively.
conclusionThe multifunctional nanotransporter approach provides a new in vivo functional platform for drug development that could, in principle, be applicable to any combination of cell surface receptor and agent (photosensitizers, oligonucleotides, radionuclides) requiring nuclear delivery to achieve maximum effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.